KK Women’s and Children’s Hospital is currently participating in an international, multicentre clinical trial to evaluate the use of an oral PDE-5 inhibitor in treating pulmonary arterial hypertension (PAH) in children where chronic therapy is needed.

What is this research study all about?

• 16-week randomized, placebo-controlled study followed by an extension study where all
  subjects will receive the active drug.

Who is eligible?

• Children aged 1-16 years
• Weighing 8 kg or more
• Patients who have symptomatic PAH

Who is not eligible?

• Patients with left-sided heart disease, pericardial constriction or;
• Moderate to severe restrictive pulmonary disease or;
• Severe or chronic lung disease, bronchopulmonary dysplasia.

For further information, please contact:

Principal Investigator: Dr. Wong Keng Yean, Email: kywong@kkh.com.sg
Study coordinator: Ms. Delphine Lim, Mobile: 9753-4837